regeneron pharmaceuticals semaglutide & Hansoh's GLP-1 Deal Semaglutide GLP-1 Receptor Agonist Research
Description
Neurologists warn that GLP-1 weight-loss drugs like semaglutide may accelerate ALS progression by triggering dangerous rapid weight loss in patients.
This article explores the science behind these agents.
In this article we review the most relevant data exploring the mechanisms involved in the effects of GLP-1RAs in the brainadipocyte axis.
Reported harms include stomach paralysis, gallbladder disease, and sudden vision loss
Order now for vibrant health!
Clinical Takeaway This analysis strengthens the hypothesis that dual incretin agonism may provide a more comprehensive metabolic benefit compared to GLP-1 receptor agonism alone
